Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001967
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2000-01-18
Brief Title:
Intermittent Versus Continuous Medication in the Treatment of HIV
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Immunologic and Virologic Studies of Intermittent Versus Continuous HAART in the Treatment of HIV Disease
Status:
COMPLETED
Status Verified Date:
2004-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Although highly active antiretroviral therapy HAART has been successful in suppressing plasma HIV RNA levels in infected patients it has not resulted in eradication of virus It is now clear that virus replication persists despite undetectable plasma viremia in individuals receiving HAART In this regard withdrawing HAART even after prolonged periods of virus suppression leads to an almost universal rapid rebound of plasma viremia It is also now clear that prolonged continuous HAART carries a risk of significant toxicity and side effects These recent observations may argue for a different approach to HAART with the goals of 1 durable suppression of virus replication without an attempt at eradication and 2 minimization of toxicity and side effects and improvement in patient life-style Therefore we propose to study the virologic and immunologic effects of intermittent versus continuous HAART in HIV-infected individuals as a possible means to achieve these goals The primary protocol Cohort 1 will be a randomized controlled study of 35 individuals receiving continuous HAART and 35 individuals receiving intermittent HAART with intervals of one month off therapy followed by two months on therapy A second cohort of 10 individuals will serve as a pilot of 2 arms of 5 patients each to evaluate the potential of shorter on-off cycles to maintain suppression of plasma virus and boost HIV-specific immune responses An extension of Cohort 2 will add 5 patients to the 7 days on7 days off HAART arm with modified exclusion criteria and procedure schedule We will analyze CD4 T-cell counts viral load incidence of toxicity and side effects HIV-specific immune responses and viral resistance to therapy and characterize the virus during rebound plasma viremia
Detailed Description:
Although highly active antiretroviral therapy HAART has been successful in suppressing plasma HIV RNA levels in infected patients it has not resulted in eradication of virus It is now clear that virus replication persists despite undetectable plasma viremia in individuals receiving HAART In this regard withdrawing HAART even after prolonged periods of virus suppression leads to an almost universal rapid rebound of plasma viremia It is also now clear that prolonged continuous HAART carries a risk of significant toxicity and side effects These recent observations may argue for a different approach to HAART with the goals of 1 durable suppression of virus replication without an attempt at eradication and 2 minimization of toxicity and side effects and improvement in patient life-style Therefore we propose to study the virologic and immunologic effects of intermittent versus continuous HAART in HIV-infected individuals as a possible means to achieve these goals The primary protocol Cohort 1 will be a randomized controlled study of 45 individuals receiving continuous HAART and 45 individuals receiving intermittent HAART with intervals of one month off therapy followed by two months on therapy A second cohort of 10 individuals will serve as a pilot study of 2 arms of 5 patients each to evaluate the potential of shorter on-off cycles to maintain suppression of plasma virus and boost HIV-specific immune responses An extension of Cohort 2 will add 5 patients to the 7 days on 7 days off HAART arm with modified exclusion criteria and procedure schedule Cohort 3 will be a pilot study of 5 individuals who will received 4 days off HAART followed by 3 days on HAART Cohort 4 will be a pilot study of 8 individuals who will receive a once-daily HAART regimen administered as short cycle intermittent therapy of 7 days off drugs followed by 7 days on drugs Cohort 5 will be a pilot study of 5 individuals who will receive 3 days off HAART followed by 4 days on HAART We will analyze CD4 T-cell counts viral load incidence of toxicity and side effects HIV-specific immune responses and viral resistance to therapy and characterize the virus during rebound plasma viremia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 00-I-0020 | None | None | None |